SUMMARY: The Presidential Commission for the Study of Bioethical Issues will conduct its fourth meeting. At this meeting, the Commission will discuss genetics, neuroscience, and neuroimaging for testing, research, diagnosis, risk identification, and health promotion. The Commission will also begin a review of human subjects protection.

DATES: The meeting will take place Monday, February 28, 2011, from 9 a.m. to approximately 4:30 p.m., and Tuesday, March 1, 2011, from 9 a.m. to approximately 12:30 p.m.

ADDRESSES: The St. Regis Hotel, Washington, DC, 923 16th and K Streets, NW., Washington, DC 20006. Phone 202-638-2626.

FOR FURTHER INFORMATION CONTACT:

www.bioethics.gov.

Hillary Wicai Viers, Communications Director, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Avenue, NW., Suite C-100, Washington, DC 20005. Telephone: 202-233-3963. E-mail: Hillary. Viers@bioethics.gov. Additional information may be obtained at http://

SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee Act of 1972, Public Law 92-463, 5 U.S.C. app. 2, notice is hereby given of the fourth meeting of the Presidential Commission for the Study of Bioethical Issues (PCSBI). The meeting will be held from 9 a.m. to approximately 4:30 p.m. on Monday, February 28, 2011, and from 9 a.m. to approximately 12:30 p.m. on Tuesday, March 1, 2011, at the St. Regis Hotel, Washington, DC. The meeting will be open to the public with attendance limited to space available. The meeting will also be webcast at http://www.bioethics.gov.

Under authority of Executive Order 13521, dated November 24, 2009, the President established PCSBI to serve as a public forum and advise him on bioethical issues generated by novel and emerging research in biomedicine and related areas of science and technology. The Commission is charged to identify and promote policies and practices that assure ethically responsible conduct of scientific research, healthcare delivery, and technological innovation. In undertaking these duties, the Commission will examine specific bioethical, legal, and social issues related to potential scientific and technological advances; examine diverse perspectives and possibilities for useful international collaboration on these issues; and recommend legal, regulatory, or policy actions as appropriate.

The main agenda items for this fourth meeting involve genetics, neuroscience, and neuroimaging; and a review of human subjects protection. Specifically, the Commission is interested in exploring social and ethical issues involving genetics, neuroscience, and neuroimaging used for research, diagnosis, risk identification, and prevention. The Commission will also begin its review of human subjects protection as requested by President Obama on November 24, 2010.

The draft meeting agenda and other information about PCSBI, including information about access to the webcast, will be available at http:// www.bioethics.gov.

The Commission welcomes input from anyone wishing to provide public comment on any issue before it. The Commission's goal, time permitting, is to invite brief public comment during each meeting session. Individuals who would like to provide public comment at the meeting should notify Esther Yoo by telephone at 202-233-3960, or e-mail at Esther. Yoo@bioethics.gov. To accommodate as many speakers as possible the time for public comments may be limited. If the number of individuals wishing to speak is greater than can reasonably be accommodated during the scheduled meeting, the Commission may randomly select speakers from among those who register to speak.

Anyone planning to attend the meeting who needs special assistance, such as sign language interpretation or other reasonable accommodations, should also notify Esther Yoo (contact information above) in advance of the meeting. The Commission will make every effort to accommodate persons who need special assistance.

Written comments will also be accepted and are especially welcome. Please address written comments by email to info@bioethics.gov, or by mail to the following address: Public Commentary, The Presidential Commission for the Study of Bioethical Issues, 1425 New York Ave., NW., Suite C-100, Washington, DC 20005. Comments will be publicly available, including any personally identifiable or confidential business information that they contain. Trade secrets should not be submitted.

Dated: February 2, 2011.

Valerie H. Bonham.

Executive Director, The Presidential Commission for the Study of Bioethical Issues. [FR Doc. 2011–3023 Filed 2–9–11; 8:45 am]

BILLING CODE 4154-06-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; National Institutes of Health **Loan Repayment Programs**

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Division of Loan Repayment, National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: National Institutes of Health Loan Repayment Programs. Type of Information Collection Request: Extension of a currently approved collection (OMB No. 0925-0361, expiration date 06/30/11). Form Numbers: NIH 2674-1, NIH 2674-2, NIH 2674-3, NIH 2674-4, NIH 2674-5, NIH 2674-6, NIH 2674-7, NIH 2674-8, NIH 2674-9, NIH 2674-10, NIH 2674-11, NIH 2674-12, NIH 2674-13, NIH 2674-14, NIH 2674-15, NIH 2674-16, NIH 2674-17, NIH 2674-18, and NIH 2674-19. Need and Use of Information Collection: The NIH makes available financial assistance, in the form of educational loan repayment, to M.D., PhD, Pharm.D., D.D.S., D.M.D., D.P.M., D.C., and N.D. degree holders, or the equivalent, who perform biomedical or behavioral research in NIH intramural laboratories or as extramural grantees or scientists funded by domestic nonprofit organizations for a minimum of 2 years (3 years for the General Research Loan Repayment Program (LRP)) in research areas supporting the mission and priorities of the NIH.

The AIDS Research LRP (AIDS-LRP) is authorized by section 487A of the Public Health Šervice Act (PHS Act) (42 U.S.C. 288-1), and the Clinical Research LRP for Individuals from Disadvantaged Backgrounds (CR-LRP) is authorized by section 487E (42 U.S.C. 288-5). The General Research LRP (GR-LRP) is authorized by section 487C of the PHS Act (42 U.S.C. 288-3), and the Clinical Research LRP (LRP-CR) is authorized by section 487F (42 U.S.C. 288-5a). The Pediatric Research LRP (PR-LRP) is authorized by section 487F of the PHS Act (42 U.S.C. 288-6), and the Extramural Clinical Research LRP for Individuals from Disadvantaged Backgrounds (ECR-LRP) is authorized by an amendment to section 487E (42 U.S.C. 288-5). The Contraception and

Infertility Research LRP (CIR–LRP) is authorized by section 487B of the PHS Act (42 U.S.C. 288–2), and the Health Disparities Research LRP (HD–LRP) is authorized by section 485G (42 U.S.C. 287c–33).

The Loan Repayment Programs can repay up to \$35,000 per year toward a

participant's extant eligible educational loans, directly to financial institutions. The information proposed for collection will be used by the Division of Loan Repayment to determine an applicant's eligibility for participation in the program. Frequency of Response: Initial application and one- or two-year

renewal application. Affected Public: Individuals or households, nonprofits, and businesses or other for-profit. Type of Respondents: Physicians, other scientific or medical personnel, and institutional representatives. The annual reporting burden is as follows:

Type of respondents	Number of respondents	Estimated number of responses per respondent	Average burden hours per response	Annual burden hours requested
Intramural LRPs:				
Initial Applicants	50	1	10.11	505.50
Advisors/Supervisors	50 140			50.00 70.00
Recommenders	140		.5	2.50
Financial institutions	10	Į.	.25	2.50
Subtotal	250			628.00
Extramural LRPs:				
Initial Applicants	2,050	1	10.75	22,037.50
Advisors/Supervisors	1,840	1	1	1,840.00
Recommenders	6,150	1	.5	3,075.00
Financial Institutions	100	1	.25	25.00
Subtotal	10,140			26,977.50
Intramural LRPs:				
Renewal Applicants	50	1	7.42	371.00
Advisors/Supervisors	50	1	2.2	110.00
Subtotal	100			481.00
Extramural LRPS:				
Renewal Applicants	1,200	1	8.58	10,296.00
Advisors/Supervisors	900		1.7	1.530.00
Recommenders	3,500		.5	1,750.00
11000111110110010	0,000		.0	1,700.00
Subtotal	5,600			13,576.00
Total	16,090			41,662.50

The annualized cost to respondents is estimated at \$1,701,641.69. The annualized cost to the Federal Government for administering the Loan Repayment Programs is expected to be \$1,448,100. This cost includes administrative support by the Division of Loan Repayment and \$800,000 for the continuing development and maintenance of the LRP Management Information System/Online Application System (MIS/OAS).

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3)

ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Milton Hernandez, PhD, Director, Division of Loan Repayment, National Institutes of Health, 6011 Executive Blvd., Room 206 (MSC 7650), Bethesda, Maryland 20892–7650. Dr. Hernandez may be contacted via e-mail at mh35c.@nih.gov or by calling 301–496–0180.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: February 4, 2011.

Lawrence A. Tabak,

Deputy Director, National Institutes of Health. [FR Doc. 2011–2995 Filed 2–9–11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials,